Drugs /

daratumumab

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
daratumumab
Trade Name(s):
Humax-Cd38 and Darzalex
NCI Definition [1]:
A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells.

Clinical Trials

View Clinical Trials for daratumumab

Daratumumab has been investigated in 91 clinical trials, of which 88 are open and 3 are closed. Of the trials investigating daratumumab, 2 are early phase 1 (2 open), 10 are phase 1 (10 open), 16 are phase 1/phase 2 (14 open), 53 are phase 2 (52 open), 1 is phase 2/phase 3 (1 open), and 9 are phase 3 (9 open).

del(17)(p10), t(4;14)(p16;q32), and IGH-FGFR3 Fusion are the most frequent biomarker inclusion criteria for daratumumab clinical trials.

Multiple myeloma, smoldering plasma cell myeloma, and chronic lymphocytic leukemia are the most common diseases being investigated in daratumumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Daratumumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Daratumumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating daratumumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
HuMax-CD38, anti-cd38 monoclonal antibody, anti-cd38 monoclonal antibody, daratumumab, daratumumab (substance), jnj-54767414, daratumumab, Darzalex
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
CD38
NCIT ID [1]:
C74007
SNOMED ID [1]:
R-FF7E4

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.